Back الأنسولين ليسبرو Arabic Inswlin Lispro Welsh Insulinpräparat#Insulin lispro German Insulina lispro Spanish انسولین لیسپرو Persian Insuline lispro French אינסולין ליספרו HE Insulin lispro ID インスリン リスプロ Japanese Insuline lispro Dutch
 | |
| Clinical data | |
|---|---|
| Trade names | Humalog, Liprolog, Admelog, others |
| Other names | URLi, LY900014, LY-275585, insulin lispro-aabc |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a697021 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Subcutaneous |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Onset of action | 30 minutes |
| Duration of action | 5 hours |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C257H389N65O77S6 |
| Molar mass | 5813.68 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Insulin lispro, sold under the brand name Humalog among others, is a modified type of medical insulin used to treat type 1 and type 2 diabetes.[5] It is delivered subcutaneously either by injection or from an insulin pump.[5][6] Onset of effects typically occurs within 30 minutes and lasts about 5 hours.[5] Often a longer-acting insulin like insulin NPH is also needed.[5]
Common side effects include low blood sugar.[5] Other serious side effects may include low blood potassium.[5] Use in pregnancy and breastfeeding is generally safe.[7] It works the same as human insulin by increasing the amount of glucose that tissues take in and decreasing the amount of glucose made by the liver.[5]
Insulin lispro was first approved for use in the United States in 1996.[5][8][9] It is a manufactured analogue of human insulin where two amino acids have swapped positions.[10] In 2022, it was the 70th most commonly prescribed medication in the United States, with more than 9 million prescriptions.[11][12]
- ^ "Insulin lispro Use During Pregnancy". Drugs.com. 7 October 2019. Archived from the original on 19 September 2020. Retrieved 23 February 2020.
- ^ "Humalog 100 units/ml, solution for injection in vial - Summary of Product Characteristics (SmPC)". (emc). 30 January 2020. Archived from the original on 23 February 2020. Retrieved 23 February 2020.
- ^ Cite error: The named reference
Humalog EPARwas invoked but never defined (see the help page). - ^ Cite error: The named reference
Liprolog EPARwas invoked but never defined (see the help page). - ^ a b c d e f g h "Insulin Lispro Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 6 March 2019. Retrieved 3 March 2019.
- ^ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 698. ISBN 9780857113382.
- ^ "Insulin lispro Pregnancy and Breastfeeding Warnings". Drugs.com. Archived from the original on 19 September 2020. Retrieved 3 March 2019.
- ^ Cite error: The named reference
Humalog labelwas invoked but never defined (see the help page). - ^ "Humalog approval" (PDF). U.S. Food and Drug Administration (FDA). 14 June 1996. Archived (PDF) from the original on 24 February 2020. Retrieved 23 February 2020.
- ^ Koivisto VA (June 1998). "The human insulin analogue insulin lispro". Annals of Medicine. 30 (3): 260–6. doi:10.3109/07853899809005853. PMID 9677011.
- ^ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
- ^ "Insulin Lispro Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.